SahirKalim Harvard Medical School/ Massachusetts General Hospital United States

SahirKalim
Dr. Kalim is a physician- scientist at Harvard Medical School and the Massachusetts General Hospital (MGH), both in Boston, USA. His research has broadly focused on understanding and modifying the unique causes of morbidity and mortality seen in chronic kidney disease. This has included translational research exploring protein modifications such as protein carbamylation and circulating metabolite alterations that occur in uremia and mechanistically contribute to adverse outcomes. His expertise has also allowed him to serve as the PI for NIH funded clinical trials including a nationwide randomized study investigating novel treatments for chronic pain in hemodialysis patients. Dr. Kalim has mentored multiple trainees and co-directs the MGH Kidney Research Center. He has won multiple clinical teaching awards, research honors, and has been awarded multiple independent NIH grants to pursue his studies. Dr. Kalim remains an active clinician caring for patients with chronic and end stage kidney disease.

Day 1 - Sunday April 14, 2024

Time Session
12:15 p.m.
1:15 p.m.
CarlaAvesani Chairperson carla.avesani@ki.seKarolinska InstituteSweden
SahirKalim Chairperson skalim@mgh.harvard.eduHarvard Medical School/ Massachusetts General Hospital United States
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - PROS
    ConnieRhee Speaker crhee@mednet.ucla.eduUCLAUnited States
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - CONS
    SwapnilHiremath Speaker shiremath@toh.caUniversity of OttawaCanada
Hall A